myeloproliferative neoplasms (MPN) | Page 3 | Aplastic Anemia & MDS International Foundation

myeloproliferative neoplasms (MPN)

Myelodysplastic/myeloproliferative Neoplasm, Unclassifiable (MDS/MPN-U): More Than Just a "Catch-All" Term?

Author(s): 
Rory M Shallis, Amer M Zeidan
Primary Author: 
Shallis, Rory M
Journal Title: 
Best practice & research. Clinical haematology
Original Publication Date: 
Jun 2020

The clinicopathology of MDS and MPN are not mutually exclusive and for this reason the category of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) exists. Several sub-entities have been included under the MDS/MPN umbrella, including MDS/MPN-unclassifiable (MDS/MPN-U) for those cases whose morphologic and clinical phenotype do not meet criteria to be classified as any other MDS/MPN sub-entity.

Bone Marrow Diseases: 

Nikolai Podoltsev, MD, PhD

Podoltsev, Nikolai
Associate Director of the Hematology/Oncology Fellowship Program
Smilow Cancer Hospital at Yale

Dr. Podoltsev practice is focused on myeloid neoplasms including acute myelogenous leukemias (AML), myelodisplastic syndromes (MDS), myeloproliferative neoplasms (MPNs) like polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), chronic myelogenous leukemia (CML) among others. He is providing care for patients with

Online Profile: 
https://www.yalemedicine.org/doctors/nikolai_podoltsev/

Thomas Prebet, MD, PhD

Prebet, Thomas
Medical Director of Hematology and Cell Therapy
Smilow Cancer Hospital at Yale

After completing his doctorate in medical hematology and oncology in Lyon, France, Dr. Prebet joined Institut Paoli-Calmettes in Marseille, France and completed a fellowship in Johns Hopkins University (Baltimore, MA, USA) as a Fullbright alumni. Dr. Prebet is currently the director of the inpatient hematology unit and the medical director of the hematology division of Yale

Online Profile: 
https://medicine.yale.edu/profile/thomas_prebet/

2020 National Virtual Patient & Family Conference

AAMDSIF hosted the 2020 National Patient & Family Conference ONLINE over three days, July 17 - 19, 2020. The Conference featured three days of educational workshops, panels and speakers for patients, families and caregivers with

Event Date: 
Fri, 07/17/2020 to Sun, 07/19/2020
2020 National Patient & Family Conference
Conference Materials: 
PDF icon Blood Transfusions, Iron Overload, and Treatment for Iron Overload - AAMDSIF Summer Conference 2020
PDF icon Caring for Caregivers - AAMDSIF Summer Conference 2020
PDF icon Changing Landscape for PNH Patients - AAMDSIF Summer Conference 2020
PDF icon Complementary and Alternative Medicines - AAMDSIF Summer Conference 2020
PDF icon How Long Do I Have to Live? Prognosis for Bone Marrow Failure Diseases - AAMDSIF Summer Conference 2020
PDF icon Is a Clinical Trial Right for Me? AAMDSIF Summer Conference 2020
PDF icon Living with Low Risk MDS - AAMDSIF Summer Conference 2020
PDF icon Managing Fatigue and Side Effects - AAMDSIF Summer Conference 2020
PDF icon Moderate and High Risk MDS / AML - AAMDSIF Summer Conference 2020
PDF icon Pediatric Bone Marrow Failure Diseases - AAMDSIF Summer Conference 2020
PDF icon PNH - A Patient Centered Approach - AAMDSIF Summer Conference 2020
PDF icon Long Term Survivorship for Bone Marrow Transplant Patients - AAMDSIF Summer Conference 2020
PDF icon AAMDSIF National Virtual Patient & Family Conference Program
Bone Marrow Diseases: 

Catriona Jamison, MD, PhD

Jamison, Catriona
Professor of Medicine
Moores Cancer Center

Catriona Jamieson, MD, PhD, is a board-certified hematologist with broad clinical expertise in caring for patients with hematologic malignancies. As hematology team leader for the Division of Hematology/Oncology at UC San Diego Health Moores Cancer Center, Dr.

Online Profile: 
https://providers.ucsd.edu/details/12046/catriona-jamieson-cancer-hematology_blood_diseases-la_jolla

omparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

This phase II trial studies how well 3 different drug combinations prevent graft versus host disease (GVHD) after donor stem cell transplant. Calcineurin inhibitors, such as

National March for Marrow 2020 - Virtual Walk/5K

We've gone VIRTUAL!
With the health and well-being of our patients, family members, friends and faculty as our top priority, AAMDSIF is holding our National March for Marrow as a VIRTUAL WALK! 

Event Date: 
Sat, 07/18/2020
Community Event Type: 
March for Marrow Walk
Bone Marrow Diseases: